Lack of association between APOE gene polymorphisms and amyotrophic lateral sclerosis: A comprehensive meta-analysis

References

• Gordon PH, Salachas F, Lacomblez L, Le Forestier N, Pradat PF, Bruneteau G, et al. Predicting survival of patients with amyotrophic lateral sclerosis at presentation: a 15-year experience. Neurodegener Dis. 2013;12:81–90.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013;9:617–28.
   PubMed Web of Science ®Google Scholar
• Andersen PM. ALS and FTD: two sides of the same coin?Lancet Neurol. 2013;12:937–8.
   PubMed Web of Science ®Google Scholar
• Neumann M. Frontotemporal lobar degeneration and amyotrophic lateral sclerosis: molecular similarities and differences. Rev Neurol (Paris). 2013;169:793–8.
   PubMed Web of Science ®Google Scholar
• Talbot K, Ansorge O. Recent advances in the genetics of amyotrophic lateral sclerosis and frontotemporal dementia: common pathways in neurodegenerative disease. Hum Mol Genet. 2006;15:182–7.
   PubMed Web of Science ®Google Scholar
• Achi EY, Rudnicki SA. ALS and Frontotemporal Dysfunction: A Review. Neurol Res Int. 2012:806306.
   Google Scholar
• Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol. 2007;6: 994–1003.
   PubMed Web of Science ®Google Scholar
• Mackenzie IR, Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 2010;9:995–1007.
   PubMed Web of Science ®Google Scholar
• DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in non-coding region of C9orf72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245–56.
   PubMed Web of Science ®Google Scholar
• Rubino E, Rainero I, Chiò A, Rogaeva E, Galimberti D, Fenoglio P, et al. SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurology. 2012;79:1556–62.
   PubMed Web of Science ®Google Scholar
• Rademakers R, Neumann M, Mackenzie IR. Advances in understanding the molecular basis of frontotemporal dementia. Nat Rev Neurol. 2012;8:423–34.
   PubMed Web of Science ®Google Scholar
• Schymick JC, Traynor BJ. Expanding the genetics of amyotrophic lateral sclerosis and frontotemporal dementia. Alzheimers Res Ther. 2012;4:30.
   PubMed Web of Science ®Google Scholar
• Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late-onset families. Science. 1993;261:921–3.
   PubMed Web of Science ®Google Scholar
• Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240: 622–30.
   PubMed Web of Science ®Google Scholar
• Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1:507–37.
   PubMed Web of Science ®Google Scholar
• Brown C, Wright E, Colton C, Sullivan PM, Laskowitz DT, Vitek MP. Apolipoprotein E isoform mediated regulation of nitric oxide release. Free Radic Biol Med. 2002; 32:1071–5.
   PubMed Web of Science ®Google Scholar
• Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer’s disease and other neurological disorders. Lancet Neurol. 2011;10:241–52.
   PubMed Web of Science ®Google Scholar
• Rannikmäe K, Samarasekera N, Martînez-Gonzâlez NA, Al-Shahi Salman R, Sudlow CL. Genetics of cerebral amyloid angiopathy: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2013;84:901–8.
   PubMed Web of Science ®Google Scholar
• Kawanishi C, Suzuki K, Odawara T, Iseki E, Onishi H, Miyakawa T, et al. Neuropathological evaluation and apolipoprotein E gene polymorphism analysis in diffuse Lewy body disease. J Neurol Sci. 1996;136:140–2.
   PubMed Web of Science ®Google Scholar
• Kálmán J, Juhász A, Majtényi K, Rimanóczy A, Jakab K, Gárdián G, et al. Apolipoprotein E polymorphism in Pick’s disease and in Huntington’s disease. Neurobiol Aging. 2000;21:555–8.
   PubMed Web of Science ®Google Scholar
• Rubino E, Vacca A, Govone F, de Martino P, Pinessi L, Rainero I. Apolipoprotein E polymorphisms in frontotemporal lobar degeneration: a meta-analysis. Alzheimers Dement. 2013;9:706–13.
   PubMed Web of Science ®Google Scholar
• Haasdijk ED, Vlug A, Mulder MT, Jaarsma D. Increased apolipoprotein E expression correlates with the onset of neuronal degeneration in the spinal cord of G93A-SOD1 mice. Neurosci Lett. 2002;335:29–33.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Enayat ZE, Bakker MC, Sham PC, Ball DM, Shaw CE, et al. Association of apolipoprotein E epsilon 4 allele with bulbar-onset motor neuron disease. Lancet. 1996;347:159–60.
   PubMed Web of Science ®Google Scholar
• Jawaid A, Poon M, Strutt AM, Rice LK, McDowell EJ, Salamone AR, et al. Does apolipoprotein E genotype modify the clinical expression of ALS?Eur J Neurol. 2011;18:618–24.
   PubMed Web of Science ®Google Scholar
• Mui S, Rebeck GW, McKenna-Yasek D, Hyman BT, Brown RH Jr. Apolipoprotein E epsilon 4 allele is not associated with earlier age at onset in amyotrophic lateral sclerosis. Ann Neurol. 1995;38:460–3.
   PubMed Web of Science ®Google Scholar
• Drory VE, Birnbaum M, Korczyn AD, Chapman J. Association of ApoE epsilon 4 allele with survival in amyotrophic lateral sclerosis. J Neurol Sci. 2001;190:17–20.
   PubMed Web of Science ®Google Scholar
• Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial ‘Clinical limits of amyotrophic lateral sclerosis’ workshop contributors. J Neurol Sci. 1994;124(Suppl 1):96–107.
   PubMedGoogle Scholar
• Brooks BR, Miller RG, Swash M. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2000;1:293–9.
   PubMed Web of Science ®Google Scholar
• Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive Meta-Analysis version 2. Englewood: Biostat; 2005.
   Google Scholar
• Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to meta-analysis. Chichester: Wiley; 2009.
   Google Scholar
• Praline J, Blasco H, Vourc’h P, Garrigue MA, Gordon PH, Camu W, et al. APOE ϵ4 allele is associated with an increased risk of bulbar-onset amyotrophic lateral sclerosis in males. Eur J Neurol. 2011;18:1046–52.
   PubMed Web of Science ®Google Scholar
• Steenland K, MacNeil J, Seals R, Levey A. Factors affecting survival of patients with neurodegenerative disease. Neuroepidemiology. 2010;35:28–35.
   PubMed Web of Science ®Google Scholar
• Schmidt S, Kwee LC, Allen KD, Oddone EZ. Association of ALS with head injury, cigarette smoking and APOE genotypes. J Neurol Sci. 2010;291:22–9.
   PubMed Web of Science ®Google Scholar
• Zetterberg H, Jacobsson J, Rosengren L, Blennow K, Andersen PM. Association of APOE with age at onset of sporadic amyotrophic lateral sclerosis. J Neurol Sci. 2008;273:67–9.
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Doppler V, Beucler I, Costes G, Salachas F, Raisonnier A, et al. ApoE: a potential marker of disease progression in ALS. Neurology. 2002;58:1112–4.
   PubMed Web of Science ®Google Scholar
• Galasko D, Salmon DP, Craig UK, Thal LJ, Schellenberg G, Wiederholt W. Clinical features and changing patterns of neurodegenerative disorders on Guam, 1997–2000. Neurology. 2002;58:90–7.
   PubMed Web of Science ®Google Scholar
• Siddique T, Pericak-Vance MA, Caliendo J, Hong ST, Hung WY, Kaplan J, et al. Lack of association between apolipoprotein E genotype and sporadic amyotrophic lateral sclerosis. Neurogenetics. 1998;1:213–6.
   PubMed Web of Science ®Google Scholar
• Gaillard O, Gervais A, Meillet D, Plassart E, Fontaine B, Lyon-Caen O, et al. Apolipoprotein E and multiple sclerosis: a biochemical and genetic investigation. J Neurol Sci. 1998;158:180–6.
   PubMed Web of Science ®Google Scholar
• Moulard B, Sefiani A, Laamri A, Malafosse A, Camu W. Apolipoprotein E genotyping in sporadic amyotrophic lateral sclerosis: evidence for a major influence on the clinical presentation and prognosis. J Neurol Sci. 1996;139: 34–7.
   PubMed Web of Science ®Google Scholar
• Bachus R, Bader S, Gessner R, Ludolph AC. Lack of association of apolipoprotein E epsilon 4 allele with bulbar-onset motor neuron disease. Ann Neurol. 1997;41:417.
   PubMed Web of Science ®Google Scholar
• van Es MA, Veldink JH, Saris CG, Blauw HM, van Vught PW, Birve A, et al. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet. 2009; 41:1083–7.
   PubMed Web of Science ®Google Scholar
• Dupré N, Valdmanis P. Genome-wide association studies in amyotrophic lateral sclerosis. Eur J Hum Genet. 2009; 17:137–8.
   PubMed Web of Science ®Google Scholar
• Ioannidis JP, Trikalinos TA, Ntzani EE, Contopoulos- Ioannidis DG. Genetic associations in large versus small studies: an empirical assessment. Lancet. 2003;361: 567–71.
   PubMed Web of Science ®Google Scholar
• Vossel KA, Bien-Ly N, Bernardo A, Rascovsky K, Karydas A, Rabinovici GD, et al. APOE and TDP-43 neuropathology in two siblings with familial FTLD-motor neuron disease. Neurocase. 2013;19:295–301.
   PubMed Web of Science ®Google Scholar
• Olney RK, Murphy J, Forshew D, Garwood E, Miller BL, Langmore S, et al. The effects of executive and behavioural dysfunction on the course of ALS. Neurology. 2005; 65:1774–7.
   PubMed Web of Science ®Google Scholar